| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Melanocortin receptors (MC1R‑MC5R) with greatly reduced affinity compared to full‑length ACTH. The fragment may interact with other unidentified binding sites.
|
|---|---|
| ln Vitro |
In vitro, ACTH 34‑39 is used to assess the minimal sequence requirements for receptor binding and activation. It shows weak or negligible agonist activity at melanocortin receptors, as the active core (His‑Phe‑Arg‑Trp) is located in the N‑terminal part. However, it serves as a negative control or as a competitor to study binding specificity. The peptide has been investigated for its effects on neuronal cultures, where it may modulate neurotransmitter release or neuronal excitability. Its stability against enzymatic degradation is moderate due to its short length.
|
| ln Vivo |
In vivo, ACTH 34‑39 has been studied in animal models for its potential role in stress‑related sleep disorders. Some reports suggest that this fragment may influence sleep patterns, possibly through mechanisms independent of classical melanocortin receptors. However, the data are limited and not firmly established. The peptide is not a therapeutic candidate; it is strictly a research compound for probing the biology of ACTH fragments and their physiological significance.
|
| Enzyme Assay |
Receptor binding assays are performed using membranes from cells expressing melanocortin receptors (e.g., MC1R, MC4R). Membranes are incubated with a radiolabeled ligand such as [¹2⁵I]‑NDP‑alpha‑MSH (0.1-0.5 nM) and increasing concentrations of ACTH 34‑39 (0.01 nM-100 microM) in binding buffer (25 mM HEPES, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 0.5% BSA) for 2 h at room temperature. Non‑specific binding is defined with 1 microM unlabeled NDP‑alpha‑MSH. Bound radioactivity is separated by filtration through GF/C filters and counted. The lack of significant competition indicates low affinity. Functional assays measure cAMP accumulation in MC4R‑expressing cells; ACTH 34‑39 is added at 0.01-100 microM, and cAMP is measured by ELISA. The peptide typically shows minimal or no stimulation.
|
| Cell Assay |
Cells stably expressing melanocortin receptors (e.g., HEK‑293‑MC4R) are seeded in 96‑well plates. ACTH 34‑39 is applied at concentrations of 0.01, 0.1, 1, 10, and 100 microM for 15-30 min. Intracellular cAMP is quantified using a competitive immunoassay. The results are compared to full‑length ACTH (1‑39) or alpha‑MSH as positive controls. If the fragment shows activity, it is typically very weak (EC₅0 > 10 microM). For studies on neuronal cells, primary cortical or hippocampal neurons may be treated with the peptide (1-100 microM) for 24-48 h, and changes in gene expression or neuronal activity are assessed by qPCR, calcium imaging, or electrophysiology.
|
| Animal Protocol |
In vivo studies are typically conducted in mice or rats. ACTH 34‑39 is administered intracerebroventricularly (ICV) at doses of 1-10 nmol per animal, or intraperitoneally at higher doses (0.1-1 mg/kg). Sleep‑wake patterns are monitored by electroencephalography (EEG) and electromyography (EMG) recordings over 4-6 h post‑injection. Behavioral tests such as open field or elevated plus maze may be performed to assess anxiety‑like behavior. For pharmacokinetic studies, blood and cerebrospinal fluid are collected at various time points, and peptide concentrations are measured by radioimmunoassay or LC‑MS/MS.
|
| ADME/Pharmacokinetics |
ACTH 34‑39 has molecular formula C3₇H₅0N₆O₉ and molecular weight 722.83. It is soluble in DMSO (90 mg/mL) and in aqueous buffers (e.g., PBS) at lower concentrations. The peptide should be stored as a lyophilized powder at -20 degC, protected from moisture and light. In solution, it is susceptible to proteolytic degradation; therefore, freshly prepared solutions are recommended. Pharmacokinetic data are scarce, but as a small peptide, it likely has a short half‑life (minutes) in circulation and is cleared by renal filtration and enzymatic breakdown.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for ACTH 34‑39. At the low doses used in research, it is generally considered non‑toxic. However, as with all research peptides, standard laboratory safety practices should be followed. It is not intended for human or veterinary use.
|
| References | |
| Additional Infomation |
ACTH 34‑39 is a synthetic hexapeptide fragment (AFPLEF) of the adrenocorticotropic hormone. It is employed as a research tool to investigate the structure‑activity relationships of ACTH, the function of its C‑terminal region, and potential roles in sleep and stress. Unlike full‑length ACTH, it has negligible activity at melanocortin receptors, making it useful as a negative control or for studying non‑receptor‑mediated effects. The peptide is not an approved drug and is available only for laboratory research. Its stability and solubility characteristics are typical of small hydrophilic peptides.
|
| Molecular Formula |
C37H50N6O9
|
|---|---|
| Molecular Weight |
722.827709674835
|
| Exact Mass |
722.363
|
| CAS # |
69454-10-0
|
| PubChem CID |
121235584
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
1111.2±65.0 °C at 760 mmHg
|
| Flash Point |
625.8±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
3.23
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
52
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N
|
| InChi Key |
FUSHTHSTTRFCPC-OBXVVNIGSA-N
|
| InChi Code |
InChI=1S/C37H50N6O9/c1-22(2)19-27(34(48)39-26(16-17-31(44)45)33(47)42-29(37(51)52)21-25-13-8-5-9-14-25)40-35(49)30-15-10-18-43(30)36(50)28(41-32(46)23(3)38)20-24-11-6-4-7-12-24/h4-9,11-14,22-23,26-30H,10,15-21,38H2,1-3H3,(H,39,48)(H,40,49)(H,41,46)(H,42,47)(H,44,45)(H,51,52)/t23-,26-,27-,28-,29-,30-/m0/s1
|
| Chemical Name |
(4S)-4-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(1S)-1-carboxy-2-phenylethyl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~138.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3835 mL | 6.9173 mL | 13.8345 mL | |
| 5 mM | 0.2767 mL | 1.3835 mL | 2.7669 mL | |
| 10 mM | 0.1383 mL | 0.6917 mL | 1.3835 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
